Physician profile
Randee M Watson
NPI 1588977656
$3,307.70
in general payments reported to CMS, 2019-2025
11 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.46 · 2021: $526 · 2022: $1,031 · 2023: $304 · 2024: $771 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $1,412.90 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $789.64 | 2023-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $262.31 | 2022-2025 | |
| Alimera Sciences, INC. | $253.67 | 2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $218.48 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $128.50 | 2024-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $95.76 | 2025 | Yutiq |
| Alcon Vision LLC | $55.46 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.11 | 2021 | |
| Biogen, INC. | $26.29 | 2023 | |
| Eyepoint US, INC. | $19.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,910.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randee Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.